Kailera Therapeutics, Inc. (KLRA) Stock Score, Valuation & Financial Research

Kailera Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for KLRA

Kailera Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 11.11. These figures are a research snapshot, not a buy or sell recommendation.

What Kailera Therapeutics, Inc. does

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Kailera Therapeutics is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model focuses on the research and development of GLP-1-based obesity therapeutics, relying on capital raises and potential future licensing or commercialization agreements to fund operations.

Products and services

  • The company is developing a pipeline of obesity treatments, including its lead candidate ribupatide (KAI-9531), a once-weekly injectable GLP-1/GIP receptor dual agonist currently in Phase 3 clinical trials.

Brands and product families

  • ribupatide (KAI-9531) — Lead clinical-stage product candidate for obesity. Source

Customer types

Patients with obesity.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on unnamed third-party contract manufacturing organizations for the production of clinical trial materials. Source

Competitors and product-market comparisons

  • Eli Lilly and Company — Competes in the development and commercialization of GLP-1 receptor agonist therapies for obesity. Source
  • Novo Nordisk A/S — Competes in the development and commercialization of GLP-1 receptor agonist therapies for obesity. Source

Business strengths to evaluate

  • Advanced clinical-stage pipeline with lead candidate in Phase 3 Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers for clinical supply Source

Sources: Company research source · ribupatide (KAI-9531)

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

KLRA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 11.11
Market capitalization:
1.44B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -148.96M
Free cash flow:
USD -122.3M
Cash:
USD 130.3M
Total debt:
USD 10.22M
EPS:
USD -1.26

What stands out

  • Free cash flow is USD -122.3M, negative for the stored period.
  • The balance sheet shows USD 130.3M of cash versus USD 10.22M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a limited financial history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 120.08M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for KLRA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can KLRA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is KLRA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for KLRA to reach sustainable profitability?
  • What does the current limited financial history warning mean for the reliability or interpretation of KLRA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 55% of the scoring inputs required for this public page are currently available.

How to research KLRA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.